Loading
A phase 1/2 trial of MT-125 in glioma & glioblastoma, run by Myosin Therapeutics Inc., now recruiting.
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients is a phase 1/2 interventional study registered as NCT07185880 by Myosin Therapeutics Inc., with 36 participants planned, started 2026-04-01 and due to reach its primary completion in 2026-10-31. Interventions recorded: MT-125.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/